Related Experiment Videos
Viral hepatitis and hepatocellular carcinoma
Peter P Michielsen1, Sven M Francque, Jurgen L van Dongen
1Division of Gastroenterology and Hepatology, University Hospital, Antwerp, Belgium. peter.michielsen@uza.be
World Journal of Surgical Oncology
|May 24, 2005
Summary
Preventing hepatocellular carcinoma (HCC) involves avoiding risk factors like viral hepatitis B and C. Vaccination for hepatitis B (HBV) is a key preventive strategy, while interferon treatments show promise for chronic hepatitis patients.
Area of Science:
- Hepatology
- Oncology
- Infectious Diseases
Background:
- Hepatocellular carcinoma (HCC) is a major global malignancy, with incidence varying geographically.
- Chronic hepatitis B (HBV) and hepatitis C (HCV) are primary drivers of HCC, particularly in cirrhotic patients.
- Rising HCC rates in developed nations are linked to increased HCV infection and improved cirrhosis management.
Purpose of the Study:
- To review the literature on hepatitis and hepatocellular carcinoma.
- To explore epidemiology, risk factors, screening, and prevention strategies for HCC.
Main Methods:
- Literature review using Medline database.
- Selection of articles based on keywords related to hepatitis and HCC.
- Focus on epidemiology, risk factors, screening, and prevention.
Main Results:
- Screening with ultrasound and alpha-fetoprotein may aid HCC detection in chronic HBV/HCV patients, but clinical outcome benefits require further study.
- HBV and HCV contribute to HCC indirectly via chronic inflammation or directly through viral proteins and HBV integration into host DNA.
- Hepatitis B vaccination shows promise in preventing HCC development.
Conclusions:
- Avoiding risk factors, especially viral infections, is crucial for HCC prevention.
- Hepatitis B vaccination is a recommended health priority.
- Interferon-alfa treatment may offer protection against HCC in non-cirrhotic chronic hepatitis B or C patients, with varying efficacy in established cirrhosis.